Miracle

Executive Summary

Miracle is a Y Combinator-backed (W2023) startup that provides a 'control room' for clinical trials, offering real-time dashboards, automated insights, and streamlined operations for biopharma companies. Founded in 2020 and based in the United States, the company addresses a critical pain point in drug development: the inefficiency and manual overhead of trial management. By centralizing data and surfacing actionable intelligence, Miracle enables sponsors and CROs to reduce delays, improve decision-making, and accelerate time-to-market. The platform taps into a large and growing market, as clinical trial complexity and data volumes continue to rise. Although still in early stages with no disclosed funding or customer metrics, Miracle's positioning as an AI-driven operational layer for trials aligns with industry trends toward digitalization and automation. If executed well, the company could become an essential infrastructure provider for biopharma, though it faces competition from established eClinical vendors and emerging analytics startups. Overall, Miracle presents a compelling thesis with moderate near-term risk due to its early commercial stage.

Upcoming Catalysts (preview)

• TBDSeries A Funding Closing70% success
• TBDFirst Major Pharma Customer60% success
• TBDNew Product Feature Launch (AI Insights)75% success